Ushering in a New Era of Medical Education at NTHU
2.10.2021 08:00:00 EEST | Business Wire | Press release
National Tsing Hua University’s plan to establish a post-baccalaureate program in medicine has been approved at a recent cross-ministerial meeting held at the Ministry of Education. The school’s recruitment and admission application process will begin by the end of 2021, and the first class of government-sponsored students will be enrolled in September 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211001005043/en/
College of Life Science dean Kao Ruey-Ho (left) and Department of Medical Science chair Chen Linyi (right) prepare for the post-baccalaureate program in medicine. (Photo: National Tsing Hua University)
NTHU President Hocheng Hong said that NTHU already has a strong foundation in cross-disciplinary research in medical science, including big data analysis, application of artificial intelligence (AI), bioengineering, material science, and nuclear medicine, by which the school is well-positioned to train physicians specializing in more than one expertise. As such, this new program represents a quantum jump in medical education in Taiwan.
President Hocheng said that NTHU already has sufficient number of faculty members, funding, and infrastructure for the new program. In addition to the existing 180 faculty members teaching related courses, the program has recently recruited an additional 71 full-time faculty members, and 87 physician scientists from leading medical centers throughout Taiwan as adjunct faculty members. Moreover, the provisional office of this program has raised NT$2 billion for medical education. An ongoing plan for establishing a state-of-the-art teaching hospital and medical complex in the Taoyuan Aerotropolis next to the Taoyuan International Airport is currently being reviewed by the Ministry of Health and Welfare.
The post-baccalaureate program in medicine is a four-year program, open for graduates from all disciplines. The government-sponsored students will be required to serve in a public healthcare facility for six years. They will have an opportunity to undertake an additional two years of advanced training in a medical center.
NTHU will draw on its extensive experience in student recruitment to admit only those applicants who meet the stringent admission qualifications, the innovative student selection process could open a new path for medical education in Taiwan.
The post-baccalaureate program in medicine will be part of the future College of Life Sciences and Medicine (currently the College of Life Science). Dean of the College of Life Science, Kao Ruey-Ho, former Superintendent of Tzu Chi Medical Center, said that applicants who apply directly to NTHU will be evaluated based on test scores, transcripts, and interviews, to select students who have demonstrated academic excellence, as well as a passion for medicine and public welfare.
Government-sponsored students in the program will take several courses designed to prepare them for practicing in a rural area, such as Community Medicine Practicum, and make good use of AI diagnosis and telemedicine technology; they will also attend seminars on altruism and dedication to public health, which will be taught by laureates of the Medical Contribution Award.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211001005043/en/
Contact information
Holly Hsueh
NTHU
(886)3-5162006
hoyu@mx.nthu.edu.tw
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 08:30:00 EET | Press release
Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2024, › Free Cash Flow of EUR 824.2 million, up 3.9% organically and up 2.6% at constant currency, and cash conversion of 107%2, › Adjusted net
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 08:00:00 EET | Press release
Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat in a mouse model in Sandhoff disease, a form of GM2 gangliosidosis with no approved treatments—alongside healthy control subjects. The research assessed how the drug’s exposure relates to its effects in the brain, demonstrating a significant increase in both survival (22%; 26 days) and assessments of movement and behavior at 16 weeks versus un
Galderma Announces Triple Approval of New State-of-the-Art Restylane ® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224651688/en/ The syringe features a next-generation ergonomic design that enhances precision and control; includes an optimized syringe-needle connection with the new Terumo K-Pack Enhance™ needle; and offers a premium color-coded packaging and syringe design to support easy range navigation for practitioners.4-7, 9,10 It sets a new standard in Injectable Aesthetic devices and demonstrates Galderma’s unwavering commitment to driving innovation to meet the needs of both practitioners and patients. “Developing this new syringe
Verdict Expected Soon in Klarna’s $8.3 Billion Antitrust Lawsuit Against Google24.2.2026 20:09:00 EET | Press release
Klarna Group plc (NYSE: KLAR) announces that the Patent and Market Court of Sweden (Patent- och marknadsdomstolen) is expected to deliver its verdict on April 15, 2026 in the antitrust damages proceedings brought by Klarna’s subsidiary PriceRunner International AB against Google LLC and Google Ireland Limited. The trial, which ran from October 20 to December 19, 2025, concerned PriceRunner’s claim for approximately $8.3 billion in damages — the largest civil damages claim ever filed in a Swedish court. The Case The claim arises from Google’s abuse of dominance in online comparison shopping, as established by the European Commission in a binding 2017 decision and upheld without reservation by the Court of Justice of the European Union in September 2024. PriceRunner alleges that Google systematically demoted competing price comparison services in its search results while favouring its own Google Shopping product, causing sustained and quantifiable commercial damage to PriceRunner over mo
INRIX Announces New Generation of AI Traffic Products: Helping to Improve Safety, Reduce Congestion, and Enhance Mobility Operations24.2.2026 17:49:00 EET | Press release
INRIX, a global leader in transportation data and analytics, today announced a major expansion of its Trafficfamily of products, delivering innovativeAI-driven capabilities to help transportation agencies and logistics organizations move from reactive traffic management to proactive, safety-focused and efficient operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224267928/en/ INRIX introduces expanded automation, generative AI capabilities, enhanced incident detection, and continuous analytics. Over twenty years ago, INRIX commercialized the first system to use GPS data to create real-time traffic information. In 2019, INRIX launched AI Traffic – the world's first traffic platform to leverage deep learning models and AI to improve the quality and analysis globally. Now, INRIX is launching a new generation of automation and intelligence to help agencies and enterprises move faster from analyzing data to making deci
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom